Couldn't have asked for a worse day to release the results. It also looks like we are going to need a webinar with Porf Miles Prince to convince the market of the significance of these resutls.
More than double the SOC duration... months duration beyond benchmark target... 40% ORR with now two complete responses.
ODD granted for all TCL cancer types with every chance of being granted a registrational study with accelerated approval as the end game. Wakey wakey Mr Market
